Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma

BACKGROUND: The GLARIUS trial, which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) compared with standard temozolomide in the first-line therapy of O(6)-methylguanine-DNA methyltransferase (MGMT)-nonmethylated glioblastoma, showed that progression-free survival was significantly pr...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Schäfer, Niklas, Proescholdt, Martin, Steinbach, Joachim P, Weyerbrock, Astrid, Hau, Peter, Grauer, Oliver, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W, Uhl, Martin, Grau, Stefan, Hänel, Mathias, Schnell, Oliver, Krex, Dietmar, Vajkoczy, Peter, Tabatabai, Ghazaleh, Mack, Frederic, Schaub, Christina, Tzaridis, Theophilos, Nießen, Michael, Kebir, Sied, Leutgeb, Barbara, Urbach, Horst, Belka, Claus, Stummer, Walter, Glas, Martin, Herrlinger, Ulrich
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2018
Предметы:
Clinical Investigations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6007398/
https://ncbi.nlm.nih.gov/pubmed/29121274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox204
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы